TCM
ACAD icon

Tandem Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Tandem Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7,858
Closed -$420K – 83
2020
Q4 		$420K Buy
7,858
+2,720
+53% +$135K 0.32% 64
2020
Q3 		$212K Buy
+5,138
New +$222K 0.19% 75

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Tandem Capital Management's ACAD Position: Q1 2021 in Review

Tandem Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2021, closing a stake of 7,858 shares — an estimated $420K sold.

Tandem Capital Management first reported a position in ACAD in Q3 2020 and held it in 2 quarters. The position peaked at $420K in Q4 2020. 272 funds tracked by Wall St. Rank hold ACAD as of Q1 2021.

  • Tandem Capital Management reported no remaining Acadia Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Tandem Capital Management sold 7,858 Acadia Pharmaceuticals shares in Q1 2021, an estimated $420K.
  • Tandem Capital Management first reported a position in Acadia Pharmaceuticals in Q3 2020 and held it in 2 quarters.
  • Tandem Capital Management's Acadia Pharmaceuticals position peaked at $420K in Q4 2020.
  • 272 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2021.

Based on Tandem Capital Management's 13F filing for Q1 2021, filed 12 May 2021.